Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
Surgical Case Reports|May 25, 2017
Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two casesYui Ishiguro, Shigenori Homma, Tadashi Yoshida, et al.The Journal of Dermatology|March 16, 2017
Two cases of melanomas paradoxically metastasizing to the intestinal tract during nivolumab therapyHajime Miyazawa, Teruki Yanagi, Yasuyuki Yamaguchi, et al.The Journal of Investigative Dermatology|January 18, 2008
Specific filaggrin mutations cause ichthyosis vulgaris and are significantly associated with atopic dermatitis in JapanToshifumi Nomura, Masashi Akiyama, Aileen Sandilands, et al.Cancer Science|September 12, 2019
Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapyNatsuko Iga, Atsushi Otsuka, Masahiro Hirata, et al.Journal of Dermatological Science|October 29, 2017
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patientsYasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, et al.Journal of Dermatological Science|July 25, 2017
Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumabYasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, et al.Plos One|January 26, 2019
Accumulation of exhausted CD8+ T cells in extramammary Paget's diseaseNatsuko Iga, Atsushi Otsuka, Yosuke Yamamoto, et al.Frontiers in Medicine|May 14, 2019
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced MelanomaTaku Fujimura, Yota Sato, Kayo Tanita, et al.Oncotarget|April 13, 2018
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot studyTaku Fujimura, Yota Sato, Kayo Tanita, et al.Frontiers in Oncology|December 5, 2018
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous MelanomaTaku Fujimura, Yota Sato, Kayo Tanita, et al.Pageof 6